MicrobiotiX is a biotechnology company specializing in the development of bacteriophage-based therapeutics aimed at combating diseases caused by multidrug-resistant bacteria. The company leverages a comprehensive platform for phage therapy development, which includes a phage library panel, an in silico module, and a cGMP-grade manufacturing facility. MicrobiotiX is pioneering efforts in Korea to conduct the first human clinical trials of phage therapy, supported by government funding to advance research and development for the commercialization of these innovative anti-infective drugs.
Leadership & Board
Key Executives
Chief Scientific OfficerZachary D. Aron
Chief Business OfficerRichard Gauthier
Founder, President & CEOTerry L. Bowlin
Current Number of Employees18
Current LinkedIn Followers911
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$20B
Total Amount Raised$20B
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$20B
Latest Funding Amount$20B
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
MicrobiotiX had 18 employees as of April 6, 2026. The number of employees increased by 0 (0.00%) week-over-week.
18Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
MicrobiotiX had 911 followers as of April 6, 2026. The number of followers increased by 1 (0.11%) week-over-week.
911Latest Followers Count
1(0.11%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.